140 related articles for article (PubMed ID: 25850580)
21. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment.
Mayer F; Gillis AJ; Dinjens W; Oosterhuis JW; Bokemeyer C; Looijenga LH
Cancer Res; 2002 May; 62(10):2758-60. PubMed ID: 12019150
[TBL] [Abstract][Full Text] [Related]
22. Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.
Fichtner A; Bohnenberger H; Elakad O; Richter A; Lenz C; Oing C; Ströbel P; Kueffer S; Nettersheim D; Bremmer F
World J Urol; 2022 Feb; 40(2):373-383. PubMed ID: 35084545
[TBL] [Abstract][Full Text] [Related]
23. Prognostic markers in clinical stage I seminoma and nonseminomatous germ cell tumours.
Pedraza AM; Stephenson AJ
Curr Opin Urol; 2018 Sep; 28(5):448-453. PubMed ID: 29979237
[TBL] [Abstract][Full Text] [Related]
24. The seminoma cell line TCam-2 is sensitive to HDAC inhibitor depsipeptide but tolerates various other chemotherapeutic drugs and loss of NANOG expression.
Nettersheim D; Gillis A; Biermann K; Looijenga LH; Schorle H
Genes Chromosomes Cancer; 2011 Dec; 50(12):1033-42. PubMed ID: 21987446
[TBL] [Abstract][Full Text] [Related]
25. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
Gizzi M; Oberic L; Massard C; Poterie A; Le Teuff G; Loriot Y; Albiges L; Baciarello G; Michels J; Bossi A; Blanchard P; Escudier B; Fizazi K
Eur J Cancer; 2016 Dec; 69():151-157. PubMed ID: 27821318
[TBL] [Abstract][Full Text] [Related]
26. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
27. [Management of localized germ-cell tumours of the testis].
Loriot Y; Fizazi K
Rev Prat; 2007 Feb; 57(4):379-84. PubMed ID: 17455739
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
29. Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.
Korkola JE; Houldsworth J; Bosl GJ; Chaganti RS
BJU Int; 2009 Nov; 104(9 Pt B):1334-8. PubMed ID: 19840009
[TBL] [Abstract][Full Text] [Related]
30. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
31. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.
Gerwing M; Jacobsen C; Dyshlovoy S; Hauschild J; Rohlfing T; Oing C; Venz S; Oldenburg J; Oechsle K; Bokemeyer C; von Amsberg G; Honecker F
J Cancer Res Clin Oncol; 2016 Sep; 142(9):1979-94. PubMed ID: 27424191
[TBL] [Abstract][Full Text] [Related]
32. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.
Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ
Eur J Cancer; 2000 Oct; 36(15):1925-32. PubMed ID: 11000572
[TBL] [Abstract][Full Text] [Related]
33. Metachronous bilateral testicular germ cell tumors: report of two cases.
James FV; Kumar A; Jayaprakash PG; Mathews A
J Cancer Res Ther; 2009; 5(3):206-7. PubMed ID: 19841564
[TBL] [Abstract][Full Text] [Related]
34. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
35. Molecular determinants of treatment response in human germ cell tumors.
Mayer F; Stoop H; Scheffer GL; Scheper R; Oosterhuis JW; Looijenga LH; Bokemeyer C
Clin Cancer Res; 2003 Feb; 9(2):767-73. PubMed ID: 12576448
[TBL] [Abstract][Full Text] [Related]
36. Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors.
McIntyre A; Summersgill B; Spendlove HE; Huddart R; Houlston R; Shipley J
Neoplasia; 2005 Dec; 7(12):1047-52. PubMed ID: 16354586
[TBL] [Abstract][Full Text] [Related]
37. Minimizing toxicity in early-stage testicular cancer treatment.
Singhera M; Lees K; Huddart R; Horwich A
Expert Rev Anticancer Ther; 2012 Feb; 12(2):185-93. PubMed ID: 22316366
[TBL] [Abstract][Full Text] [Related]
38. Treatment of early stage testicular seminoma.
Classen J; Souchon R; Hehr T; Bamberg M
J Cancer Res Clin Oncol; 2001 Aug; 127(8):475-81. PubMed ID: 11501746
[TBL] [Abstract][Full Text] [Related]
39. Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy.
Timmerman JM; Northfelt DW; Small EJ
J Clin Oncol; 1995 Jun; 13(6):1391-7. PubMed ID: 7538557
[TBL] [Abstract][Full Text] [Related]
40. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials.
Bokemeyer C; Kollmannsberger C; Stenning S; Hartmann JT; Horwich A; Clemm C; Gerl A; Meisner C; Rückerl CP; Schmoll HJ; Kanz L; Oliver T
Br J Cancer; 2004 Aug; 91(4):683-7. PubMed ID: 15266338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
